143 related articles for article (PubMed ID: 29350066)
1. Differential expression of cytokeratin 14 and 18 in bladder cancer tumorigenesis.
Li YP; Jia XP; Jiang YQ; Wang W; Wang YL; Wang XL; Guo YX
Exp Biol Med (Maywood); 2018 Feb; 243(4):344-349. PubMed ID: 29350066
[TBL] [Abstract][Full Text] [Related]
2. Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis.
Gil da Costa RM; Oliveira PA; Vasconcelos-Nóbrega C; Arantes-Rodrigues R; Pinto-Leite R; Colaço AA; de la Cruz LF; Lopes C
Int J Exp Pathol; 2015 Oct; 96(5):319-25. PubMed ID: 26515584
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Expression of Cyclin D1, Cytokeratin 20, and Uroplakin III in Proliferative Urinary Bladder Lesions Induced by o-Nitroanisole in Fischer 344/N Rats.
Willson CJ; Flake GP; Sills RC; Kissling GE; Cesta MF
Vet Pathol; 2016 May; 53(3):682-90. PubMed ID: 26319780
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer.
Chen Y; Cui T; Yang L; Mireskandari M; Knoesel T; Zhang Q; Pacyna-Gengelbach M; Petersen I
Oncology; 2011; 80(5-6):333-40. PubMed ID: 21791943
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways of urothelial development and bladder tumorigenesis.
Castillo-Martin M; Domingo-Domenech J; Karni-Schmidt O; Matos T; Cordon-Cardo C
Urol Oncol; 2010; 28(4):401-8. PubMed ID: 20610278
[TBL] [Abstract][Full Text] [Related]
6. Comparative immunohistochemical study of ameloblastoma and ameloblastic carcinoma.
Yoon HJ; Jo BC; Shin WJ; Cho YA; Lee JI; Hong SP; Hong SD
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Dec; 112(6):767-76. PubMed ID: 22014999
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in rats.
Oliveira PA; Colaço A; De la Cruz LF; Lopes P; Lopes C
J Exp Clin Cancer Res; 2006 Sep; 25(3):425-32. PubMed ID: 17167984
[TBL] [Abstract][Full Text] [Related]
8. BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.
Mohanty SK; Lai JP; Gordon OK; Pradhan D; Bose S; Dadmanesh F
Breast J; 2015; 21(6):596-603. PubMed ID: 26390986
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
[TBL] [Abstract][Full Text] [Related]
10. The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice.
Dai YC; Wang SC; Haque MM; Lin WH; Lin LC; Chen CH; Liu YW
PLoS One; 2017; 12(10):e0186214. PubMed ID: 29016672
[TBL] [Abstract][Full Text] [Related]
11. Squamous and transitional elements in rat bladder carcinomas induced by N-butyl-N-4-hydroxybutyl-nitrosamine (BBN). A study of cytokeratin expression.
Herman CJ; Vegt PD; Debruyne FM; Vooijs GP; Ramaekers FC
Am J Pathol; 1985 Sep; 120(3):419-26. PubMed ID: 2412446
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification.
Yuk HD; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
BMC Cancer; 2019 Sep; 19(1):897. PubMed ID: 31500577
[TBL] [Abstract][Full Text] [Related]
13. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
14. DNA cytophotometric and histological analysis of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced precancerous lesions of the bladder urothelium.
Dahm HH; von der Haar C; Rübben H
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1253-60. PubMed ID: 27033373
[TBL] [Abstract][Full Text] [Related]
15. [The changes of population and distribution of S-phase cells in precancerous lesions of rat bladder revealed by the method of bromodeoxyuridine labeling].
Hashimoto H; Sasaki M; Fujisawa M; Kaneko S; Tokunaka S; Yachiku S
Nihon Hinyokika Gakkai Zasshi; 1990 Oct; 81(10):1518-24. PubMed ID: 2273703
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of p27 kip1 knockout mice to urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine may not simply be due to enhanced proliferation.
Hikosaka A; Ogawa K; Sugiura S; Asamoto M; Takeshita F; Sato SY; Nakanishi M; Kohri K; Shirai T
Int J Cancer; 2008 Mar; 122(6):1222-8. PubMed ID: 18027869
[TBL] [Abstract][Full Text] [Related]
17. [Animal models of bladder cancer].
Fukushima S
Hinyokika Kiyo; 1988 Nov; 34(11):1923-7. PubMed ID: 3242366
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of UPIa, UPIb, UPII, and UPIIIa during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats.
Zupančič D; Ovčak Z; Vidmar G; Romih R
Virchows Arch; 2011 May; 458(5):603-13. PubMed ID: 21301865
[TBL] [Abstract][Full Text] [Related]
19. Development of Urinary Bladder Pre-Neoplasia by
Chala B; Choi MH; Moon KC; Kim HS; Kwak C; Hong ST
Korean J Parasitol; 2017 Feb; 55(1):21-29. PubMed ID: 28285503
[No Abstract] [Full Text] [Related]
20. Dose response of saccharin in induction of urinary bladder hyperplasias in Fischer 344 rats pretreated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Nakanishi K; Hagiwara A; Shibata M; Imaida K; Tatematsu M; Ito N
J Natl Cancer Inst; 1980 Nov; 65(5):1005-10. PubMed ID: 6933236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
